Accelerate Diagnostics

Accelerate Diagnostics Financing Cash Flow

Delisted

The Net Financing Cash Flow of Accelerate Diagnostics (AXDX) as of Nov 10, 2026 is 27.05 M USD. In the previous year, Net Financing Cash Flow was 9.02 M USD — a change of 199.96% (higher).

Financing Cash Flow

27.05 MUSD

YoY

199.96%

Last updated:

Net Financing Cash Flow of Accelerate Diagnostics is 2024 27.05 M USD. Net Financing Cash Flow of Accelerate Diagnostics was 2023 9.02 M USD. It decreases by 199.96% higher compared to the previous year.

The Accelerate Diagnostics Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
90.43 M USD
Jan 1, 2018
125.77 M USD
Jan 1, 2019
6.82 M USD
Jan 1, 2020
11.63 M USD
Jan 1, 2021
43.23 M USD
Jan 1, 2022
31.63 M USD
Jan 1, 2023
9.02 M USD
Jan 1, 2024
27.05 M USD
The Accelerate Diagnostics Financing Cash Flow history
YEARFinancing Cash FlowYoY
27.05 MUSD+199.96%
9.02 MUSD-71.49%
31.63 MUSD-26.83%
43.23 MUSD+271.58%
11.63 MUSD+70.50%
6.82 MUSD-94.58%
125.77 MUSD+39.09%
90.43 MUSD+5,032.07%
1.76 MUSD-98.32%
104.82 MUSD+129.42%
45.69 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

Net Financing Cash Flow of Accelerate Diagnostics is 27.05 M USD in 2024.

Net Financing Cash Flow of Accelerate Diagnostics changed from 9.02 M USD to 27.05 M USD, representing a 199.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Accelerate Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics